BAY-1075553 F-18

Details

Stereochemistry	EPIMERIC
Molecular Formula	C6H10FO7P
Molecular Weight	243.1141
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C([18F])C[C@H](CP(O)(O)=O)C(O)=O

InChI

InChIKey=SJIJEWUUIKDXIM-KMRZSKAOSA-N

InChI=1S/C6H10FO7P/c7-4(6(10)11)1-3(5(8)9)2-15(12,13)14/h3-4H,1-2H2,(H,8,9)(H,10,11)(H2,12,13,14)/t3-,4?/m1/s1/i7-1

HIDE SMILES / InChI

Molecular Formula	C6H10FO7P
Molecular Weight	243.1141
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	1 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:43:36 GMT 2023` Edited by `admin` on `Sat Dec 16 11:43:36 GMT 2023`
Record UNII	7Y9R4VZJ3P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BAY-1075553 F-18

Code

English

(18F)BAY-1075553

Code

English

BAY 1075553

Code

English

PENTANEDIOIC ACID, 2-(FLUORO-18F)-4-(PHOSPHONOMETHYL)-, (2SR,4S)-

Systematic Name

English

(2SR,4S)-2-(FLUORANYL-18F)-4-(PHOSPHONOMETHYL)PENTANEDIOIC ACID

Systematic Name

English

Code System Code Type Description

FDA UNII

7Y9R4VZJ3P

Created by admin on Sat Dec 16 11:43:36 GMT 2023 , Edited by admin on Sat Dec 16 11:43:36 GMT 2023

PRIMARY

PUBCHEM

71559387

Created by admin on Sat Dec 16 11:43:36 GMT 2023 , Edited by admin on Sat Dec 16 11:43:36 GMT 2023

PRIMARY

CAS

1312438-66-6

Created by admin on Sat Dec 16 11:43:36 GMT 2023 , Edited by admin on Sat Dec 16 11:43:36 GMT 2023

PRIMARY

Related Record Type Details


					DRF6ZX9D07

PROSTATE SPECIFIC MEMBRANE ANTIGEN

TARGET->RADIOLIGAND

Amount:

Related Record Type Details


					7Y9R4VZJ3P

BAY-1075553 F-18

ACTIVE MOIETY

Comments:

RESULTS: There were no relevant changes in laboratory values or physical examination. Urinary bladder wall received the largest dose equivalent 0.12 mSv/MBq. The whole-body mean effective dose was 0.015 mSv/MBq. There was a significant correlation between detected prostatic lesions by the two imaging modalities (Kappa=0.356, P<0.001) and no significant difference in sensitivity (P=0.16) and specificity (P=0.41). The sensitivity and specificity of PET imaging using BAY1075553 for lymph node (LN) staging was 42.9 % and 100 %, while it was 81.2 % and 50 % using FCH. The two modalities were closely correlated regarding detection of LNs and bone metastases, although BAY1075553 failed to detect a bone marrow metastasis. Degenerative bone lesions often displayed intense uptake of BAY1075553. CONCLUSIONS: BAY1075553 PET-CT produced no adverse effects, was well tolerated, and detected primary and metastatic prostate cancer. FCH PET-CT results were superior, however, with respect to detecting LN and bone marrow metastases.


					7Y9R4VZJ3P

BAY-1075553 F-18

ACTIVE MOIETY

Comments:

Purpose Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed in prostate cancer and is therefore being explored as a biomarker for diagnosing and staging of the disease. Here we report preclinical data on BAY 1075553 (a 9:1 mixture of (2S,4S)- and (2R,4S)-2-(18F) fluoro-4-phosphonomethyl-pentanedioic acid), a novel 18Flabelled smallmolecule inhibitor of PSMA enzymatic activity, which can be efficiently synthesized from a direct radiolabelling precursor.